



Therapeutic Capacity of Apoptotic Mononuclear Cell Secretome in Experimental Spinal Cord Injury

Doctoral viva


Thomas Haider, M.D.

CHRISTIAN DOPPLER LABORATORY
for the Diagnosis & Regeneration of Cardiac and Thoracic Diseases
Medical University of Vienna
www.meduniwien.ac.at/applied-immunology

Vienna, March 29, 2016


Introduction

Stem Cell Therapy



J Clin Neurol 2016;12(1):14-20

Introduction



J Clin Neurol 2016;12(1):14-20

Introduction


Table 1 | Randomized trials in patients with acute myocardial infarction or ischemic heart failure

Trial name	Number of patients	Cell type	Dose	Route of delivery	Timing of delivery	Primary end point	Comments
Acute myocardial infarction							
BOOST	60	nBMC	128ml	i.c.	Day 6±1	LVEF ↑	Effect diminished after 18 and 61 months
REPAIR-AMI	187	mnBMC	50ml	i.c.	Day 3–6	LVEF ↑	NA
Leuven-AMI	66	mnBMC	130ml	i.c.	Day 1	LVEF ↔	Regional contractility ↑ Infarct size ↓
ASTAMI	97	mnBMC	50ml	i.c.	Day 6±1	LVEF ↔	NA
FINCELL	77	mnBMC	80ml	i.c.	Day 3	LVEF ↑	NA
REGENT	117	mnBMC (unselected vs CD34 ⁺ /CXCR4 ⁺)	50–70ml (unselected) 100–120ml (selected)	i.c.	Day 3–12	LVEF ↑ with both cell types	NA
HEBE	189	mnBMC vs mnPBC	60ml (mnBMC) 150ml (mnPBC)	i.c.	Day 3–8	Regional contractility ↔	NA
Ischemic heart failure							
MAGIC	97	SkM	400 or 800×10 ⁶	i.m.	>Week 4	LVEF ↔	LVEDV ↓ LVESV ↓
TOPCARE-CHD	58	mnBMC vs CPC	50ml	i.c.	Month 81±72	LVEF ↑ (mnBMC) LVEF ↔ (CPC)	NA

Nat. Rev. Cardiol. 2010; 7: 204-215.

Introduction


Myocardial Infarction



The Dying Stem Cell Hypothesis by Anker *et al.*

up to 25% of all transplanted cells are in the state of apoptosis

apoptotic cells induce transient immunosuppression




Introduction

Stem Cell Engraftment and Transdifferentiation?

- Low number of transplanted cells
- Permanent engraftment not observable
- Therapeutic effect in less than 72h
- Secretome (CM) alone delivers comparable results

Circ Res. 2008 Nov 21; 103(11): 1204–1219.

Introduction




Stem Cells International, Volume 2015, Article ID 765846

Introduction


Comparability of BMCs and PBMCs Secretome

- Secretome: D
 - 25 secreted factors
 - 10 secreted factors



European Heart Journal (2008) 29, 2851–2858 .

Introduction




Introduction

- Attenuation of acute myocardial infarction

(Lichtenauer et al; Basic Res Cardiol. 2011)


Macroscopic analysis after 24 hours

Medium IV



(a)


APOSEC IV



(b)

Introduction

- Attenuation of acute myocardial infarction
(Lichtenauer et al; Basic Res Cardiol. 2011)
- Immunosuppression in an experimental myocarditis model
(Hoetzencker et al; Eur Heart J. 2013)





Introduction

- Attenuation of acute myocardial infarction
(Lichtenauer et al; Basic Res Cardiol. 2011)
- Immunosuppression in an experimental myocarditis model
(Hoetzencker et al; Eur Heart J. 2013)
- Inhibition of MVO and thrombocyte activation
(Hoetzencker et al; Bas Res Cardiol 2012)


Introduction

- Attenuation of acute myocardial infarction
(Lichtenauer et al; Basic Res Cardiol. 2011)
- Immunosuppression in an experimental myocardial infarction model
(Hoetzencker et al; Eur Heart J. 2013)
- Inhibition of MVO and thrombocyte activation
(Hoetzencker et al; Bas Res Cardiol 2012)
- Wound healing in a murine and porcine wound model
(Mildner et al; PLoS One. 2013)




Introduction

- Attenuation of acute myocardial infarction
(Lichtenauer et al; Basic Res Cardiol. 2011)
- Immunosuppression in an experimental myocarditis model
(Hoetzencker et al; Eur Heart J. 2013)
- Inhibition of MVO and thrombocyte activation
(Hoetzencker et al; Bas Res Cardiol 2012)
- Wound healing in a murine and porcine wound model
(Mildner et al; PLoS One. 2013)
- **Experimental stroke model**
(Altmann et al; F1000Res. 2014 Jun 19 [revised 2014 Oct 28])






Introduction



Altmann et al., F1000Res. 2014 Jun 19






Introduction



Altmann et al., F1000Res. 2014 Jun 19

Introduction



Induction of Apoptosis



Beer et al. BMC Genomics 2014

Introduction

Compounds of the Secretome





Lichtenauer et. Al Basic Res Cardiol. 2011 Nov;106(6):1283-97.

	2,5*10^6
IL-8 (pg/ml)	2305,8 ±136,4
GRO-alpha (pg/ml)	487,7 ±89,5
ENA-78 (pg/ml)	37857,5 ±12734,2
MCP-1 (pg/ml)	739,9 ±175,5
NAP-2 (μg/ml)	9,9 ±0,5
RANTES (pg/ml)	22251,2 ±3641,9
sICAM-1 (pg/ml)	2068,2 ±415,2
VEGF ₁₆₅ (pg/ml)	640,1 ±35,2
IL-16 (pg/ml)	1254,2 ±77,6
IL-1ra (pg/ml)	410,7 ±167,0
IL-10 (pg/ml)	7,1 ±0,5
IGF-I (pg/ml)	5,8 ±3,2
HGF (pg/ml)	72,9 ±19,1
FGF-2 (pg/ml)	534,2 ±11,6
TGF-beta (pg/ml)	87,3 ±20,4
MMP9 (pg/ml)	3612,3 ±597,7
MIF (pg/ml)	20147,5 ±1140,2
PAI-1 (pg/ml)	5060,6 ±3247,5
SDF-1 (pg/ml)	148,5 ±7,1

Introduction

Compounds of the Secretome


- Secreted Proteins
- Oxidized Lipids
- Extracellular vesicles
 - Microparticles
 - Exosomes



Beer et al. BMC Genomics 2014

Introduction

Spinal Cord Injury



Introduction

Spinal Cord Injury





- 50 per 1 million annually worldwide (200/year in AUT)
- Average age of patients : 31 years
- 50% experience total loss of motor function
- 2 out of 3 – cervical spinal cord affected



J Neurosurg. 1991; 75(1): 15-26.
J Neurotrauma. 2004; 21(10): 1355-70.

Introduction

Spinal Cord Injury



The Spine Journal 2004; 4(4): 451-64.

Introduction

Spinal Cord Injury – Treatment

- Early surgical decompression
- Corticosteroids (?) – Methylprednisolone (MP) regime
- Rehabilitation

J Neurotrauma 2011; 28: 1371-1399


Introduction

Spinal Cord Injury – Treatment

- 30 years of SCI research -> 1 approved treatment option (MP) aside from surgical therapy
- Recommendation for the use of MP in SCI was revoked in 2013 by the AANS


J Neurotrauma 2011; 28: 1371-1399

Introduction



The Spine Journal 2004; 4(4): 451-64.

Introduction



Front. Cell. Neurosci. 2013; 4.

Hypothesis

Compounds of secretome of apoptotic peripheral blood mononuclear cells exert therapeutic capacity

Methods

Contusion Injury Model

BBB-Score



J Neurotrauma. 2003; 20(2): 179-93.
J Neurotrauma. 1995; 12(1): 1-21.

Methods

Venous Blood Withdrawal



Cell Separation



Irradiation



Incubation for 24h



Centrifugation




Lyophilization



Lyophilized MNC-secretomes Virus Elimination (GMP)



Methods




Exp Neurol. 2015; 267: 230-242.




-RESULTS-

Results





Exp Neurol. 2015; 267: 230-242.

Results





Exp Neurol. 2015; 267: 230-242.

Results









Exp Neurol. 2015; 267: 230-242.

Results





Exp Neurol. 2015; 267: 230-242.

Results



Exp Neurol. 2015; 267: 230-242.


Results




Exp Neurol. 2015; 267: 230-242.

Results


Medium






MNC-secretome




C



D




Results







Exp Neurol. 2015; 267: 230-242.

Previous Results




Basic Res Cardiol. 2011 Jun;106(4):645-55.

Results




Results



Bio Protocoll 2015, e1671 m2302014

Results




Exp Neurol. 2015; 267: 230-242.

Summary

- Secretome of apoptotic PBMCs previously attributed with
 - Cytoprotection/Inhibition of apoptosis
 - Immunomodulation
 - Inhibition of microvascular obstruction/thrombocyte activation
- Translatable to Spinal Cord Injury

Exp Neurol. 2015; 267: 230-242.

Summary



TTND. 2016; 3:e1198.

Summary

- Secretome of apoptotic PBMCs lead to
 - Improvement of neurologic outcome
 - Attenuation of morphological damage
 - Improvement of vascularity
 - Recruitment of peripheral monocytes

-> Multilayered therapy

Exp Neurol. 2015; 267: 230-242.

Outlook

- Crossing of the blood-brain barrier?
- Alternative administration route/Combination with novel approaches
- Mechanisms involved in monocyte recruitment?
- Translation to bed-side

Acknowledgments



Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration

Hendrik Jan Ankersmit
Patrick Altmann
Andreas Mitterbauer
Matthias Zimmermann
Lucian Beer
Mahdi Mohammad Kasiri

Institute of Neurology/Neuropathology

Romana Höftberger
Irene Leißer
Eva Dassler
Gerda Ricken
Mirjam Lutz

Department of Transfusion Medicine

Beate Rüger
Tanja Buchacher

Department of Pediatrics

Gert Lubec

Department of Dermatology

Michael Mildner
Bahar Golabi

Center for Brain Research

Simon Hametner

LBI Experimental and Clinical Traumatology


Heinz Redl
Jens Hartmann
Markus Rossmann

Red Cross Blood Transfusion Service Linz

Christian Gabriel




Addendum



Exp Neurol. 2015; 267: 230-242.

Addendum




TNF and Increased Intracellular Iron Alter Macrophage Polarization to a Detrimental M1 Phenotype in the Injured Spinal Cord

Antje Kroner,¹ Andrew D. Greenhalgh,¹ Juan G. Zarruk,¹ Rosmarini Passos dos Santos,¹ Matthias Gaestel,² and Samuel David^{1,*}

¹Centre for Research in Neuroscience, The Research Institute of the McGill University Health Center, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada

²Institute of Biochemistry, Hannover Medical School, 30625 Hannover, Germany



Exp Neurol. 2015; 267: 230-242.